(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (“we”, the “Company” or the “Registrant”), which is the registrant, and those of vTv Therapeutics LLC (“vTv LLC”), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the “Company”, “we”, “us” and “our” refer to vTv Therapeutics Inc. and its consolidated subsidiaries.

	September 30,			December 31,			June 30,			December 31,
	2018			2017			2019			2018
	(Unaudited)						(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	3,766		$	11,758		$	1,462		$	1,683
Restricted cash and cash equivalents		—			162
Accounts receivable, net		—			8,000			1,822			—
Prepaid expenses and other current assets		1,006			442			145			666
Current deposits		1,124			—			367			1,124
Total current assets		5,896			20,362			3,796			3,473
Restricted cash and cash equivalents, long-term		2,500			2,500			2,500			2,500
Property and equipment, net		177			283			54			70
Operating lease right-of-use assets								167			—
Long-term investments		2,480			2,480			2,480			2,480
Long-term deposits		36			2,292			75			36
Total assets	$	11,089		$	27,917		$	9,072		$	8,559
Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit
Current liabilities:
Accounts payable and accrued expenses	$	8,965		$	13,901		$	8,326		$	7,702
Operating lease liabilities								178			—
Current portion of deferred revenue		6,747			8,757			27			1,752
Current portion of notes payable		9,597			4,271			8,646			9,383
Total current liabilities		25,309			26,929			17,177			18,837
Notes payable		8,611			15,316
Notes payable, net of current portion								2,185			6,330
Deferred revenue, net of current portion		595			4,497			1,052			1,067
Warrant liability, related party		382			492			1,240			2,436
Other liabilities		258			290			260			260
Total liabilities		35,155			47,524			21,914			28,930
Commitments and contingencies
Redeemable noncontrolling interest		19,912			131,440			37,060			62,482
Stockholders’ deficit:
Class A Common Stock, $0.01 par value; 100,000,000 shares authorized, 15,772,449 and 9,693,254 shares outstanding as of September 30, 2018 and December 31, 2017, respectively		158			97
Class B Common Stock, $0.01 par value; 100,000,000 shares authorized, 23,094,221 and 23,119,246 shares outstanding as of September 30, 2018 and December 31, 2017, respectively		232			232
Class A Common Stock, $0.01 par value; 100,000,000 shares authorized, 29,826,782 and 20,347,065 shares outstanding as of June 30, 2019 and December 31, 2018, respectively								298			203
Class B Common Stock, $0.01 par value; 100,000,000 shares authorized, and 23,094,221 outstanding as of June 30, 2019 and December 31, 2018								232			232
Additional paid-in capital		144,617			127,682			167,125			150,595
Accumulated deficit		(188,985	)		(279,058	)		(217,557	)		(233,883	)
Total stockholders’ deficit attributable to vTv Therapeutics Inc.		(43,978	)		(151,047	)		(49,902	)		(82,853	)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit	$	11,089		$	27,917		$	9,072		$	8,559

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

	Three Months Ended						Nine Months Ended						Three Months Ended						Six Months Ended
	September 30,						September 30,						June 30,						June 30,
	2018			2017			2018			2017			2019			2018			2019			2018
Revenue	$	3,375		$	15		$	7,912		$	58		$	1,828		$	2,473		$	2,749		$	4,537
Operating expenses:
Research and development		2,698			8,989			20,235			29,572			4,228			8,594			7,050			17,537
General and administrative		2,158			2,567			7,150			8,396			2,392			2,737			4,778			4,992
Total operating expenses		4,856			11,556			27,385			37,968			6,620			11,331			11,828			22,529
Operating loss		(1,481	)		(11,541	)		(19,473	)		(37,910	)		(4,792	)		(8,858	)		(9,079	)		(17,992	)
Other income		10			—			46			—			1			—			1			36
Other income – related party		319			—			610			—			275			316			1,196			291
Interest income		13			35			47			95			16			16			26			34
Interest expense		(822	)		(849	)		(2,547	)		(2,240	)		(514	)		(870	)		(1,140	)		(1,725	)
Loss before income taxes and noncontrolling interest		(1,961	)		(12,355	)		(21,317	)		(40,055	)		(5,014	)		(9,396	)		(8,996	)		(19,356	)
Income tax provision		—			—			200			—			100			200			100			200
Net loss before noncontrolling interest		(1,961	)		(12,355	)		(21,517	)		(40,055	)		(5,114	)		(9,596	)		(9,096	)		(19,556	)
Less: net loss attributable to noncontrolling interest		(1,165	)		(8,705	)		(14,697	)		(28,222	)		(2,232	)		(6,524	)		(4,059	)		(13,532	)
Net loss attributable to vTv Therapeutics Inc.	$	(796	)	$	(3,650	)	$	(6,820	)	$	(11,833	)	$	(2,882	)	$	(3,072	)	$	(5,037	)	$	(6,024	)
Net loss attributable to vTv Therapeutics Inc. common shareholders													$	(2,882	)	$	(3,072	)	$	(8,765	)	$	(6,024	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.06	)	$	(0.38	)	$	(0.64	)	$	(1.22	)	$	(0.10	)	$	(0.31	)	$	(0.34	)	$	(0.61	)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted		12,305,949			9,693,254			10,701,599			9,693,254			28,037,628			10,049,831			25,464,562			9,875,743

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit - Unaudited

Class A Common Stock

Class B Common Stock

Redeemable
Noncontrolling
Interest

Shares

Amount

Shares

Amount

Additional
Paid-in
Capital

Accumulated Deficit

Total Stockholders' Deficit

Balances at December 31, 2017
$
131,440

9,693,254

$
97

23,119,246

$
232

$
127,682

$
(279,058
)

$
(151,047
)
Net loss

(14,697
)

—

—

—

—

—

(6,820
)

(6,820
)
Cumulative effect of accounting
   change

—

—

—

—

—

—

213

213

Share-based compensation

—

—

—

—

—

2,345

—

2,345

Exchange of Class B Common Stock
   for Class A Common Stock

(151
)

25,025

—

(25,025
)

—

151

—

151

Issuance of Class A Common Stock
   to a related party under the Letter
   Agreements

—

6,042,503

61

—

—

14,939

—

15,000

Issuance of Letter Agreement
   and warrants to purchase Class
   A Common Stock - related party

—

—

—

—

—

(500
)

—

(500
)
Vesting of restricted stock units

—

11,667

—

—

—

—

—

—

Change in redemption value of
   noncontrolling interest

(96,680
)

—

—

—

—

—

96,680

96,680

Balances at September 30, 2018
$
19,912

15,772,449

$
158

23,094,221

$
232

$
144,617

$
(188,985
)

$
(43,978
)

For the three months ended June 30, 2019
				Class A Common Stock				Class B Common Stock
	Redeemable Noncontrolling Interest			Shares		Amount		Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balance at March 31, 2019	$	45,106			27,255,963	$	273		23,094,221	$	232	$	162,249	$	(220,489	)	$	(57,735	)
Net loss		(2,232	)		—		—		—		—		—		(2,882	)		(2,882	)
Share-based compensation		—			—		—		—		—		401		—			401
Issuance of Class A Common Stock to a related party under the Letter Agreements		—			2,570,819		25		—		—		4,475		—			4,500
Change in redemption value of noncontrolling interest		(5,814	)		—		—		—		—		—		5,814			5,814
Balances at June 30, 2019	$	37,060			29,826,782	$	298		23,094,221	$	232	$	167,125	$	(217,557	)	$	(49,902	)

For the three months ended June 30, 2018
				Class A Common Stock				Class B Common Stock
	Redeemable Noncontrolling Interest			Shares		Amount		Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balances at March 31, 2018	$	120,397			9,729,946	$	97		23,094,221	$	232	$	128,796	$	(277,913	)	$	(148,788	)
Net loss		(6,524	)		—		—		—		—		—		(3,072	)		(3,072	)
Share-based compensation		—			—		—		—		—		803		—			803
Issuance of Class A Common Stock to a related party under the Letter Agreements		—			1,141,552		12		—		—		4,988		—			5,000
Change in redemption value of noncontrolling interest		(74,460	)		—		—		—		—		—		74,460			74,460
Balances at June 30, 2018	$	39,413			10,871,498	$	109		23,094,221	$	232	$	134,587	$	(206,525	)	$	(71,597	)

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit - Unaudited

For the six months ended June 30, 2019
				Class A Common Stock				Class B Common Stock
	Redeemable Noncontrolling Interest			Shares		Amount		Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balances at December 31, 2018	$	62,482			20,347,065	$	203		23,094,221	$	232	$	150,595	$	(233,883	)	$	(82,853	)
Net loss		(4,059	)		—		—		—		—		—		(5,037	)		(5,037	)
Share-based compensation		—			—		—		—		—		682		—			682
Issuance of Class A Common Stock under registered direct offering		—			3,636,364		37		—		—		5,406		—			5,443
Issuance of Class A Common Stock to a related party under the Letter Agreements		—			5,831,687		58		—		—		10,442		—			10,500
Vesting of restricted stock units		—			11,666		—		—		—		—		—			—
Change in redemption value of noncontrolling interest		(21,363	)		—		—		—		—		—		21,363			21,363
Balances at June 30, 2019	$	37,060			29,826,782	$	298		23,094,221	$	232	$	167,125	$	(217,557	)	$	(49,902	)

For the six months ended June 30, 2018
				Class A Common Stock				Class B Common Stock
	Redeemable Noncontrolling Interest			Shares		Amount		Shares			Amount		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balances at December 31, 2017	$	131,440			9,693,254	$	97		23,119,246		$	232	$	127,682	$	(279,058	)	$	(151,047	)
Net loss		(13,532	)		—		—		—			—		—		(6,024	)		(6,024	)
Cumulative effect of accounting change		—			—		—		—			—		—		213			213
Share-based compensation		—			—		—		—			—		1,766		—			1,766
Exchange of Class B Common Stock for Class A Common Stock		(151	)		25,025		—		(25,025	)		—		151		—			151
Issuance of Class A Common Stock to a related party under the Letter Agreements		—			1,141,552		12		—			—		4,988		—			5,000
Vesting of restricted stock units		—			11,667		—		—			—		—		—			—
Change in redemption value of noncontrolling interest		(78,344	)		—		—		—			—		—		78,344			78,344
Balances at June 30, 2018	$	39,413			10,871,498	$	109		23,094,221		$	232	$	134,587	$	(206,525	)	$	(71,597	)

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

	Nine Months Ended September 30,						Six Months Ended June 30,
	2018			2017			2019			2018
Cash flows from operating activities:
Net loss before noncontrolling interest	$	(21,517	)	$	(40,055	)	$	(9,096	)	$	(19,556	)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
(Gain) loss on disposal of property and equipment, net		(12	)		(11	)
Loss (gain) on disposal of property and equipment, net								—			(12	)
Depreciation expense		111			152			16			81
Share-based compensation expense		2,345			2,657			682			1,766
Change in fair value of warrants, related party		(610	)		—			(1,196	)		(291	)
Amortization of debt discount		795			753			335			547
Changes in assets and liabilities:
Accounts receivable		8,000			—			(1,822	)		5,730
Prepaid expenses and other assets		(1,475	)		(113	)		1,278			(1,920	)
Long-term deposits		2,256			(317	)		(39	)		2,256
Accounts payable and accrued expenses		(4,936	)		(1,293	)		635			(757	)
Deferred revenue		(5,912	)		(21	)		(1,740	)		(2,537	)
Other liabilities		(32	)		19			—			(34	)
Net cash used in operating activities		(20,987	)		(38,229	)		(10,947	)		(14,727	)
Cash flows from investing activities:
Proceeds from sale of assets		12			32			—			12
Purchases of property and equipment		(5	)		(39	)
Net cash provided by (used in) investing activities		7			(7	)
Net cash provided by investing activities								—			12
Cash flows from financing activities:
Issuance of Class A Common Stock to a related party under the Letter Agreements		15,000			—
Proceeds from debt issuance		500			7,500
Proceeds from issuance of Class A Common Stock to a related party under the Letter Agreements								10,500			5,000
Proceeds from issuance of Class A Common Stock, net of offering costs								5,443			—
Repayment of notes payable		(2,674	)		—			(5,217	)		(1,042	)
Net cash provided by financing activities		12,826			7,500			10,726			3,958
Net decrease in cash, cash equivalents and restricted cash and cash equivalents		(8,154	)		(30,736	)		(221	)		(10,757	)
Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period		14,420			51,505			4,183			14,420
Total cash, cash equivalents and restricted cash and cash equivalents, end of period	$	6,266		$	20,769		$	3,962		$	3,663

Non-cash activities:
Change in redemption value of noncontrolling interest	$	(96,680	)	$	36,349		$	(21,363	)	$	(78,344	)
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock	$	151		$	—		$	—		$	151
Issuance of Letter Agreement and warrants to purchase vTv Therapeutics Inc. Class A Common Stock to a related party	$	500		$	—

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company was formed to discover and develop orally administered small molecule drug candidates to fill significant unmet medical needs.

vTv Therapeutics Inc. is a holding company and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.

The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. As of ~~September~~June 30, ~~2018,~~2019, various holders own non-voting interests in vTv LLC, representing a ~~59.4%~~43.6% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to ~~40.6%~~56.4% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of Class B Common Stock) for shares of Class A Common Stock (or cash) pursuant to the Exchange Agreement (as defined in Note 8)9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015 and its registered direct offering in March 2019, its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016, and its entrance into the letter agreements, dated as of December 5, 2017, ~~and~~ July 30, 2018, December 11, 2018 and March 18, 2019 with MacAndrews and Forbes Group LLC (the “Letter Agreements”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC outside of its obligations pertaining to the Loan Agreement as a co-borrower. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. The creditors of vTv LLC do not have any recourse to the general credit of vTv Therapeutics Inc. except as allowed under the provisions of the Loan Agreement. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.

To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through ~~September~~June 30, ~~2018,~~2019, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of ~~September~~June 30, ~~2018,~~2019, the Company had an accumulated deficit of ~~$189.0~~$217.6 million and has generated net losses in each year of its existence.

In March 2019, the Company completed a registered direct offering through which it sold 3,636,364 shares of its Class A Common Stock and raised net proceeds of approximately $5.4 million, net of related transaction costs. Further, the Company entered into an additional Letter Agreement with MacAndrews and Forbes Group LLC (the “March 2019 Letter Agreement”) under which it may sell, at the Company’s option, up to 5,454,546 shares of its Class A Common Stock at a fixed price of $1.65 per share for aggregate proceeds of up to $9.0 million during a one-year period after the date of the March 2019 Letter Agreement (the “Investment Period”). The March 2019 Letter Agreement also permits MacAndrews and Forbes Group LLC to exercise an option to purchase Class A Common Stock at the same price up to three times during the Investment Period.

As of ~~September~~June 30, ~~2018,~~2019, the Company’s liquidity sources included cash and cash equivalents of ~~$3.8~~$1.5 million, ~~and $5.0~~$7.0 million of remaining funds available under the Letter ~~Agreements. Management estimates that these sources~~Agreements and amounts due under our license agreements with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Newsoara License Agreement”) and JDRF International, net of ~~funding will allow the Company to continue its operations and activities for a period of less than twelve months from the issuance of these Condensed Consolidated Financial Statements.~~

applicable taxes. Based on the Company’s current operating plan, management believes that its current cash and cash equivalents and the remaining funds available under the Letter Agreements will allow the Company to meet its liquidity requirements into ~~December 2018.~~

~~Though~~ the ~~Company’s expected cash needs for~~third quarter of 2019, which is less than twelve months from the ~~foreseeable future have been significantly reduced with the discontinuation~~issuance of the STEADFAST and open label extension studies, the Company will require additional financing to continue its operations. The Company is seeking possible additional partnering opportunities for its GKA, GLP-1r and other drug candidates which it believes may provide additional cash for use in its operations and the continuation of clinical trials for its drug candidates. The Company is also

pursuing other sources of financing to provide flexibility to its operating plan. The timing and availability of such financing is not yet known. The failure of the STEADFAST Study to meet either co-primary endpoint may make it more difficult for the Company to obtain such financing.these Condensed Consolidated Financial Statements. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

In June 2019, the Company began screening for a Phase 2 trial to evaluate azeliragon as a potential treatment of mild-AD in patients with type 2 diabetes. Further, the Company continues to conduct the Phase 2 clinical trial of TTP399 in patients with type 1 diabetes. In order to complete these trials and continue its operations, the Company will require additional financing. The Company is evaluating several financing strategies to provide continued funding which may include additional direct equity investments or future public offerings of our common stock. The timing and availability of such financing is not yet known.

The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of ~~September~~June 30, ~~2018,~~2019, Condensed Consolidated Statements of Operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the ~~nine~~three and six months ended ~~September~~June 30, 2019 and 2018 and Condensed Consolidated Statements of Cash Flows for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, ~~2017~~2018 contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of ~~September~~June 30, ~~2018,~~2019, the results of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 and cash flows for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017.~~2018. The December 31, ~~2017~~2018 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.

The financial data and other information disclosed in these notes to the financial statements related to the three and ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 are unaudited. Interim results are not necessarily indicative of results for an entire year.

The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of derivative liabilities, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.

~~The accounts receivable balance at December 31, 2017 related to an upfront payment received in the first quarter of 2018 pursuant to the Company’s license agreement with~~ ~~Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”)~~.

Three customers represented 100% of the revenue earned during each of the three and ~~nine~~six months ended ~~September~~June 30, ~~2018. One customer represented 100% of the revenue earned during the three~~2019 and ~~nine months ended September 30, 2017.~~2018.

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted cash and cash equivalents, current as of December 31, 2017 was $0.2 million. This amount was received through a research, development and commercialization agreement with JDRF (the “JDRF Agreement”). There were no amounts held as restricted cash and cash equivalents as of September 30, 2018 related to this agreement. Restricted cash and cash equivalents, long-term as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017~~2018 was $2.5 million at each date. These amounts relate to the minimum balance that the Company must maintain in a deposit account that is pledged to secure the Loan Agreement and is subject to an account control agreement pursuant to the Loan Agreement.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017~~2018 that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows (in thousands):

In connection with the ~~License Agreement~~license agreement with Reneo Pharmaceuticals, Inc. (“Reneo”) (the “Reneo License Agreement”), the Company received common stock ~~and certain participation rights~~ representing a minority equity interest in Reneo that is classified as a long-term investment in the Company’s Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017. This investment is accounted for under the cost method because the~~2018. The Company owns less than 20% of the voting equity of Reneo and does not have the ability to exercise significant influence over Reneo.

On January 1, 2018, the Company adopted ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”. This guidance requires equity investments to be measured at fair value with changes in fair value recognized in net income. Since it does not have a readily determinable market value, the Company has elected to measure its investment in Reneo at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.

No adjustments ~~have been~~were made to the value of the Company’s investment in Reneo for the three and ~~nine~~six months ended ~~September~~June 30, 2019 and 2018 either due to impairment or based on observable price changes.

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in the Condensed Consolidated Balance Sheets. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease right-of-use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

~~On January 1, 2018,~~The Company uses the ~~Company adopted~~revenue recognition guidance established by ASC Topic 606, “Revenue From Contracts With Customers” (“ASC Topic 606”), using the modified retrospective method applied to those contracts which were not completed as of the adoption date. Results for reporting periods beginning after January 1, 2018 are presented under ASC Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC Topic 605.

The Company recorded a net reduction to its opening accumulated deficit of $0.2 million as of January 1, 2018 due to the cumulative impact of adopting ASC Topic 606, with the impact primarily related to the recognition of an asset for the incremental costs of obtaining contracts..

The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied.

The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernable pattern over which the services will be provided.

Major components of research and development costs include cash and share-based compensation, ~~depreciation expense on research and development property and equipment,~~ costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities costs, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.

The Company records accruals based on estimates of the services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.

Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue From Contracts With Customers”, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The Company adopted this guidance as of January 1, 2018 using the modified retrospective transition method. See Note 2 – “Revenue Recognition” for further details.

In January 2016, the FASB issued ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”, which amends ASC 825-10, “Financial Instruments – Overall”. This ASU amends various aspects of the recognition, measurement, presentation and disclosure of financial instruments. This ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted this guidance in the first quarter of fiscal 2018. The Company has elected to use the measurement alternative, defined as cost, less impairments, adjusted by observable price changes. The adoption of this guidance did not have a material impact on the Company’s Condensed Consolidated Financial Statements. See Note 2 – “Investments” for further details.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), which clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU 2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company adopted this guidance in the first quarter of fiscal 2018. The adoption of this guidance did not have a material impact on the Company's Condensed Consolidated Financial Stateme~~nts.~~

In February 2016, the FASB issued ASU No. 2016-02, “Lease (Topic 842)” (“ASU 2016-02”), which increases transparency and comparability among companies accounting for lease transactions. The ~~most significant change of~~Company adopted this update will require the recognition by a lessee of lease assets and liabilities on its balance sheet for operating lease arrangements with lease terms greater than 12 months. This update will requireguidance effective January 1, 2019 using a modified retrospective application ~~which includes~~and recorded a ~~number~~cumulative-effect adjustment at the beginning of ~~optional practical expedients related to~~ the ~~identification and classification~~period of ~~leases commenced before the effective date. This ASU is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2018.~~adoption. The adoption ~~of this guidance will result~~resulted in the recognition of $0.3 million of additional assets and liabilities related to the Company’s operating leases within its Condensed Consolidated Balance Sheets. See Note 7 for further details.

~~On December 21, 2017, the~~The Company ~~entered into~~is party to the Reneo License Agreement, under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta (PPAR-δ) agonist program, including the compound HPP593, for therapeutic, prophylactic or diagnostic application in humans. ~~Under the terms of the Reneo License Agreement, Reneo paid the Company an upfront cash payment of $3.0 million.~~

The Company ~~is eligible~~has fully allocated the transaction price to receive additional potential development, regulatory and sales-based milestone payments totaling up to $94.5 million. In addition, Reneo is obligated to pay the Company royalty payments at mid-single to low-double digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company has also received common stock and certain participation rights representing a minority equity interest in Reneo.

Pursuant to the terms of the Reneo License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC Topic 606, the Company identified all of the performance obligations at the inception of the Reneo License Agreement. The significant obligations were determined to be the license and the technology transfer ~~services. The Company has determined that the license and technology transfer~~ services, ~~represent~~which represents a single combined performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation. The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of September 30, 2018, as it is not considered probable that such payments will be received. The unrecognized amount of the transaction price allocatedrevenue related to this performance obligation was recognized on a straight-line basis over the technology transfer service period.

The revenue related to this performance obligation has been fully recognized as of ~~September~~June 30, 2019. For the three months ended June 30, 2019 and 2018, ~~was $2.6 million.~~the Company has recognized revenue related to this performance obligation of $0.8 million and $0.9 million, respectively. For the six months ended June 30, 2019 and 2018 the Company has recognized revenue of $1.7 million and $1.8 million, respectively related to this performance obligation. There have been no adjustments to the transaction price for this performance obligation during the three and six months ended June 30, 2019 and 2018.

The Company determined that there was no discernable pattern in which the technology services would be provided during the transfer services period. As such, the Company determined that the straight-line method would be usedis party to recognize revenue over the transfer service period. The remainder of this performance obligation will be recognized over approximately 8.5 months. For the three and nine months ended September 30, 2018, $0.9 million and $2.7 million of revenue has been recognized related to this combined performance obligation, respectively.

~~On December 21, 2017, the Company entered into~~ a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. Under the terms of the Huadong License Agreement, Huadong paid the Company an initial license fee of $8.0 million and is obligated to pay potential development and regulatory milestone payments totaling up to $25.0 million, with an additional potential regulatory milestone of $20.0 million if Huadong receives regulatory approval for a central nervous system indication. In addition, the Company is eligible for an additional $50.0 million in potential sales-based milestones, as well as royalty payments ranging from low-single to low-double digit rates, based on tiered sales of licensed products.

Under the Huadong License Agreement, the Company is also responsible for conducting a Phase 2 multi-region clinical trial (the “Phase 2 MRCT”) including sites in both the United States and Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes. The Phase 2 MRCT will be designed to satisfy the requirements of the China

Food and Drug Administration necessary in order for Huadong to begin a Phase 3 clinical trial in China. The Company will also be responsible for contributing up to $3.0 million in connection with the Phase 2 MRCT.

~~In accordance with ASC Topic 606, the Company identified all of the performance obligations at the inception of the Huadong License Agreement.~~ The significant performance obligations under this license agreement were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date (iii) the obligation to sponsor and conduct the Phase 2 MRCT, (iv) the Company’s obligation to participate on a joint development committee (the “JDC”), and (v) other obligations considered to be de minimis in nature.

~~The transaction price has been allocated to these performance obligations based on their relative standalone selling prices, which were estimated using~~ ~~an expected cost plus margin approach.~~ The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of September 30, 2018, as it is not considered probable that such payments will be received.

The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernable pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company ~~determined that~~recognized the revenue related to this combined performance obligation using the straight-line method ~~would be used to recognize revenue for this performance obligation~~ over the transfer service period. The ~~unrecognized amount of the transaction price allocated~~revenue related to this combined performance obligation has been fully recognized as of ~~$3.3 million will be~~June 30, 2019. No revenue related to this combined performance obligation was recognized ~~over approximately 8.5 months.~~during the three and six months ended June 30, 2019. For the three and ~~nine~~six months ended ~~September~~June 30, 2018, ~~$1.2~~$1.1 million and ~~$3.5~~$2.3 million of revenue ~~has been~~was recognized related to this combined performance obligation, respectively.

The ~~Company also determined that~~portion of the transaction price allocated to the obligation to sponsor and conduct a portion of the Phase 2 MRCT ~~should be treated~~was $1.0 million and remained deferred as ~~a separate performance obligation. A portion~~ of ~~the total consideration received under the Huadong License Agreement was allocated to~~June 30, 2019. Revenue for this performance obligation ~~based on its estimated standalone selling price. This amount was deferred as of September 30, 2018 and revenue~~ will be recognized using the proportional performance model over the period during which the Company conducts the Phase 2 MRCT trial. No revenue for this performance obligation has yet been ~~recognized during the three and nine months ended September 30, 2018.~~recognized.

The ~~Company also determined that~~portion of the transaction price allocated to the obligation to participate in the joint development committee (the “JDC”) to oversee the development of products and the Phase 2 MRCT in accordance with the development plan should be treated as a separate performance obligation. A portion of the total consideration received under the Huadong License Agreement was allocated to this performance obligation based on its estimated standalone selling price. This amount wasremained deferred as of ~~September~~June 30, ~~2018~~2019 and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of June 30, 2019 was $0.1 million. An immaterial amount of revenue for this performance obligation has been recognized during the three and ~~nine~~six months ended ~~September~~June 30, 2019.

There have been no adjustments to the transaction price for the performance obligations under the Huadong License Agreement during the three months ended June 30, 2019 and 2018.

~~On May 31, 2018, the~~The Company ~~entered into~~is party to a license agreement with Newsoara ~~Biopharma Co., Ltd.,~~ ~~(“Newsoara”) (the “Newsoara License Agreement”)~~, under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China, Hong Kong, Macau, Taiwan and other pacific rim countries (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory. ~~Under the terms of the Newsoara License Agreement, Newsoara paid the Company an upfront cash payment of $2.0 million.~~

The Company ~~is eligible~~has fully allocated the transaction price to receive additional potential development, regulatory and sales-based milestone payments totaling up to $63.0 million. In addition, Newsoara is obligated to pay the Company royalty payments at high-single to low-double digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country.

Pursuant to the terms of the Newsoara License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC Topic 606, the Company identified all of the performance obligations at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the technology transfer ~~services. The Company has determined that the license and technology transfer~~ services ~~represent~~which represents a single performance obligation because they were not capable of being distinct on their own. The ~~transaction price has been fully allocated to this combined performance obligation. The remaining milestone payments that the~~ Company is eligible to receive have not been included in the transaction price as of September 30, 2018, as it is not considered probable that such payments will be received. The unrecognized amount of the transaction price allocated torecognized revenue for this performance obligation ~~as of September 30, 2018 was $0.3 million.~~

~~The Company determined that there was no discernable pattern in which the technology services would be provided during the transfer services period. As such, the Company determined that~~using the straight-line method ~~would be used to recognize revenue~~ over the transfer service period. The ~~remainder of~~revenue for this performance obligation ~~will be~~has been fully recognized ~~over approximately 0.5 months. For~~as of June 30, 2019. The Company recognized revenue related to this performance obligation of $1.0 million for each of the three and ~~nine~~six months ended ~~September~~June 30, ~~2018, $1.3~~2019 and recognized revenue of $0.4 million for each of the three and ~~$1.7~~six months ended June 30, 2018. During the three and six months ended June 30, 2019, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the license agreement. This amount

was fully recognized as revenue during the three and six months ended June 30, 2019, as the related performance obligation has been ~~recognized related to this combined performance obligation, respectively.~~fully satisfied.

In August 2017, the Company entered into ~~the~~a research and collaboration agreement with JDRF ~~Agreement~~International (the “JDRF Agreement”) to support the funding of the Simplici-T1 Study, ~~an adaptive~~a Phase ~~1b/~~2 study to explore the effects of TTP399 in type 1 diabetics. The Company ~~initiated~~has completed the ~~Phase~~Sentinel and Part 1 portions of this study and has begun enrolling patients in the Part 2 portion of ~~this study in~~ the ~~second quarter of 2018.~~study. According to the terms of the JDRF Agreement, JDRF will provide research funding of up to $3.0 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of TTP399 as a treatment for type 1 diabetes.

Payments that the Company receives from JDRF under this agreement will be recorded as restricted cash and current liabilities and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of ~~September~~June 30, ~~2018,~~2019, the Company had received funding under this agreement of ~~$0.8~~$1.6 million. Research and development costs ~~were~~have been offset by a total of ~~$0.8~~$1.6 million over the course of this agreement. As of ~~September~~June 30, ~~2018,~~2019, the Company has also recognized ~~restricted cash~~a receivable of ~~an immaterial amount~~$0.8 million related to additional milestones achieved under this agreement. No such amounts were outstanding as of June 30, 2018.

Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):

The change in the Company’s contract liabilities for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 of $1.7 million was due to the recognition of ~~revenue based on~~amounts included in the ~~estimated performance~~contract liability at the beginning of ~~services under~~ the ~~related collaboration agreements as well as the recognition~~period. The Company also recognized an additional $1.0 million of ~~deferred~~ revenue related to ~~the Company’s Newsoara License Agreement. There were no~~ changes in the estimated transaction prices for ~~the related~~one of its customer contracts during the three and ~~nine~~six months ended ~~September~~June 30, ~~2018.~~2019 for which the related performance obligation had already been satisfied.

During the three and ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, the Company issued non-qualified stock option awards to certain employees of the Company. These option awards vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of ~~September~~June 30, ~~2018,~~2019, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately ~~$1.6~~$2.3 million, which is expected to be recognized over a weighted average period of ~~1.5~~2.1 years. The weighted average grant date fair value of option grants during the ~~nine~~six months ended ~~September~~June 30, 2019 and 2018 was $1.94 and ~~2017 was $2.28 and $4.17~~$2.30 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at ~~September~~June 30, ~~2018~~2019 was $0.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions:

The following table summarizes the activity related to the stock option awards for the ~~nine~~six months ended ~~September~~June 30, ~~2018:~~2019:

The following table summarizes the activity related to the RSU awards for the ~~nine~~six months ended ~~September~~June 30, ~~2018:~~2019:

As of ~~September~~June 30, ~~2018,~~2019, the ~~Company had~~ total unrecognized stock-based compensation expense ~~for its~~and the aggregate intrinsic value related to the Company’s outstanding RSU awards ~~of approximately $0.1 million, which is expected to be recognized over a weighted-average period of 1.4 years. The aggregate intrinsic value of the RSUs outstanding at September 30, 2018 was~~were both de minimis.

Compensation expense related to the grants of stock options and RSUs is included in research and development and general and administrative expense as follows (in thousands):

In October 2016, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation and Silicon Valley Bank, under which the Company and vTv LLC borrowed $20.0 million.

Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month London Interbank Offer Rate (“LIBOR”) exceeds 0.5%.

The Company borrowed the first tranche of $12.5 million upon close of the Loan Agreement in October 2016. The first tranche requires only monthly interest payments until May 1, 2018 followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on May 1, 2020. In addition, a final payment for the first tranche loan equal to $0.8 million will be due on May 1, 2020, or such earlier date specified in the Loan Agreement. The Company borrowed the second tranche of $7.5 million in March 2017. The second tranche requires only monthly interest payments until October 1, 2018 followed by equal monthly

payments of principal plus accrued interest through the scheduled maturity date on October 1, 2020. In addition, a final payment for

the second tranche loan equal to $0.5 million will be due on October 1, 2020, or such earlier date specified in the Loan Agreement. The availability of the third tranche of $5.0 million expired unused on June 30, 2017.

If the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the Lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance equal to 4.0% during the first 18 months following the funding of the second tranche and 2.0% thereafter.

The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets. ~~As a result of the termination of the STEADFAST Study, the~~The Company has granted the Lenders a first priority security interest in all of the Company’s intellectual property, subject to certain limited exceptions. The Company has agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions.

The Loan Agreement includes customary affirmative and restrictive covenants, including, but not limited to, restrictions on the payment of dividends or other equity distributions and the incurrence of debt or liens upon the assets of the Company or its subsidiaries. The Loan Agreement does not contain any financial maintenance covenants other than a requirement to maintain a minimum cash balance of not less than $2.5 million in a deposit account pledged to secure the Loan Agreement and subject to an account control agreement. ~~The minimum cash balance covenant was included as part of an amendment to the Loan Agreement in connection with the entry into the Huadong License Agreement in December 2017.~~ The Loan Agreement includes customary events of default, including payment defaults, covenant defaults, and material adverse change default. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5.0% will be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

In connection with the Loan Agreement, the Company issued to the Lenders warrants to purchase shares of the Company’s Class A Common Stock (the “Warrants”). On October 28, 2016, the Company issued Warrants to purchase 152,580 shares of its Class A Common Stock at a per share exercise price of $6.39 per share, which aggregate exercise price represents 6.0% of the principal amount borrowed under the first tranche of the Loan Agreement and 3.0% of the amount available under the second tranche of the Loan Agreement. On March 24, 2017, in connection with the funding of the second tranche, the Company issued Warrants to purchase 38,006 shares of its Class A Common Stock at a per share exercise price of $5.92 per share, which aggregate exercise price represents 3.0% of the principal amount of the second tranche of the Loan Agreement. In each instance, the Warrants have an exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.

The costs incurred in connection with the Loan Agreement, along with the allocated fair value of the Warrants issued of $0.9 million were treated as a debt discount and are offset against the carrying value of the notes payable in the Company’s Condensed Consolidated Balance Sheet as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017.~~2018. These costs will be recognized as interest expense over the term of the first tranche using the effective interest method. The final payments for the first and second loan tranches of $0.8 million and $0.5 million, respectively, will be accrued as additional interest expense, using the effective interest method, over the term of the relevant tranche.

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.

In May 2015, the Company entered into a worldwide exclusive agreement with Columbia University (“Columbia”) to license certain intellectual property from Columbia. Under the agreement, the Company is obligated to pay to Columbia (1) an annual fee of $0.1 million from 2015 through 2021, (2) a potential regulatory milestone payment of $0.8 million and (3) potential royalty payments at a single digit royalty rate based on net sales of licensed products as defined in the agreement.

In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo License Agreement”) whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as TTP399. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the Novo License Agreement, the Company has additional potential developmental and regulatory milestone payments totaling up to $115.0 million for approval of a product. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.

Under the terms of the Huadong License Agreement, vTv LLC is responsible for sponsoring the Phase 2 MRCT including sites in both the US and the Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes. vTv LLC will be responsible for contributing up to $3.0 million in connection with the Phase 2 MRCT.

The Company leases its headquarters location under an operating lease expiring in December 2019. In connection with its adoption of ASC Topic 842, the Company recognized a right of use asset and corresponding operating lease liability of $0.3 million related to this lease as of January 1, 2019. The Company elected to use the package of practical expedients in implementing ASC Topic 842 under which the Company did not reassess the operating or finance lease classification of its previously existing leases. Further, the Company did not reassess whether expired or existing contracts include leases. The discount rate used in determining the operating lease liability was 15.2%.

Operating lease cost recognized for the three and six months ended June 30, 2019 and 2018 was $0.1 million for each of the three-month periods and $0.2 million for each of the six-month periods.

Future minimum lease payments under non-cancelable operating leases to be paid in 2019 as of June 30, 2019 and December 31, 2018 were $0.2 million and $0.4 million, respectively. There are no material future minimum lease payments under non-cancellable operating leases to be made in the year 2020 or thereafter.

The Company is subject to the Exchange Agreement with respect to the vTv Units representing the ~~59.4%~~43.6% noncontrolling interest in vTv LLC outstanding as of ~~September~~June 30, ~~2018~~2019 (see Note 8)9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B Common Stock for (i) shares of Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A Common Stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.

The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017,~~2018, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of ~~$19.9~~$37.1 million and ~~$131.4~~$62.5 million, respectively.

Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:

As of ~~September~~June 30, ~~2018,~~2019, subsidiaries and affiliates of MacAndrews & Forbes Incorporated (collectively “MacAndrews”) indirectly controlled 23,084,267 shares of the Company’s Class B Common Stock and ~~8,658,169~~19,064,472 shares of the Company’s Class A Common

Stock. As a result, MacAndrews’ holdings represent approximately ~~81.7%~~79.6% of the combined voting power of the Company’s outstanding common stock.

The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:

The Company has entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the Company has the right to sell to MacAndrews shares of its Class A Common Stock at a specified price per share, and MacAndrews has the right (exercisable up to three times) to require the Company to sell to it shares of Class A Common Stock at the same price. ~~An aggregate of~~ ~~$10.0 million worth of Class A Common Stock may be sold under each of the Letter Agreements (whether at the Company’s or MacAndrews’ option).~~ In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A Common Stock.

~~The critical~~Certain terms of these Letter Agreements are set forth in the table below:

	December 5, 2017 Letter Agreement		July 30, 2018 Letter Agreement		December 5, 2017 Letter Agreement		July 30, 2018 Letter Agreement		December 11, 2018 Letter Agreement		March 18, 2019 Letter Agreement
Aggregate dollar value to be sold under agreement					$10.0 million		$10.0 million		$10.0 million		$9.0 million
Specified purchase price per share	$	4.38	$	1.33	$	4.38	$	1.33	$	1.84	$	1.65
Expiration date of letter agreement	December 5, 2018		July 30, 2019		December 5, 2018		July 30, 2019		December 11, 2019		March 18, 2020
Shares available to be issued under related warrants		198,267		518,654		198,267		518,654		340,534		—
Exercise price of related warrants	$	5.04	$	1.53	$	5.04	$	1.53	$	2.12	$	—
Expiration date of related warrants	December 5, 2024		July 30, 2025		December 5, 2024		July 30, 2025		December 11, 2025
Total shares issued as of September 30, 2018		2,283,105		3,759,398
Remaining shares to be issued as of September 30, 2018		—		3,759,399
Total shares issued as of June 30, 2019						2,283,105		7,518,797		5,434,783		1,212,121
Remaining shares to be issued as of June 30, 2019						—		—		—		4,242,425

The March 18, 2019 Letter Agreement resulted in a deemed distribution of $3.7 million to MacAndrews as the fair value of the financial instruments issued to MacAndrews exceeded the fair value of the financial instrument received by the Company. This deemed distribution has been reflected as an increase to the net loss attributable to common shareholders of vTv Therapeutics Inc. for computing net loss per share.

The Company and MacAndrews are party to an exchange agreement (the “Exchange Agreement”) pursuant to which the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Company’s Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the “Board of Directors”). As of ~~September~~June 30, ~~2018,~~2019, MacAndrews had not exchanged any shares under the provisions of this agreement.

The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.

As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor has it made any payments pursuant to the Tax Receivable Agreement as of ~~September~~June 30, ~~2018.~~2019.

The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A Common Stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.

The Company is subject to U.S. federal income taxes as well as state taxes. The Company recorded an income tax provision of $0.1 million for the three and six months ended June 30, 2019 and $0.2 million for the ~~nine~~three and six months ended ~~September~~June 30, ~~2018 representing~~2018. These amounts relate to the foreign withholding taxes ~~incurred~~paid in connection with payments recognized under the Newsoara License Agreement. ~~The Company did not record an income tax provision for the three and nine months ended September 30, 2017.~~

Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% at ~~September~~June 30, ~~2018~~2019 is due to the valuation allowance against the Company’s expected net operating losses.

As discussed in Note 8,9, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to

realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of ~~September~~June 30, ~~2018.~~

On December 22, 2017, the U.S. federal government enacted comprehensive tax reform commonly referred to as the Tax Cuts and Jobs Act (“TCJA”). Under ASC Topic 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. Among other things, the TCJA (1) reduces the U.S federal statutory corporate income tax rate from 35% to 21% effective January 1, 2018, (2) eliminates the corporate alternative minimum tax, (3) eliminates the Section 199 deduction, and (4) changes rules related to uses and limitations of net operating loss carryforwards beginning after December 31, 2017.

The SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of TCJA. SAB 118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting under ASC Topic 740. To the extent that a company’s accounting for certain income tax effects of the TCJA is incomplete but is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.

The TCJA reduces the corporate tax rate to 21% effective January 1, 2018. While we are able to make a reasonable estimate of the impact of the reduction in the corporate rate, it may be affected by other analyses related to the TCJA. The Company will continue to assess and refine, as necessary, its accounting for the TCJA as additional guidance and interpretation is provided.2019.

Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows (in thousands, except share and per share amounts):

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2018			2017			2018			2017			2019			2018			2019			2018
Numerator:
Net loss	$	(1,961	)	$	(12,355	)	$	(21,517	)	$	(40,055	)	$	(5,114	)	$	(9,596	)	$	(9,096	)	$	(19,556	)
Less: Net loss attributable to noncontrolling interests		(1,165	)		(8,705	)		(14,697	)		(28,222	)		(2,232	)		(6,524	)		(4,059	)		(13,532	)
Net loss attributable to vTv Therapeutics Inc., basic and diluted	$	(796	)	$	(3,650	)	$	(6,820	)	$	(11,833	)
Net loss attributable to vTv Therapeutics Inc.														(2,882	)		(3,072	)		(5,037	)		(6,024	)
Less: Deemed distribution to related party (Note 9)														—			—			(3,728	)		—
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted														(2,882	)		(3,072	)		(8,765	)		(6,024	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		12,305,949			9,693,254			10,701,599			9,693,254			28,037,628			10,049,831			25,464,562			9,875,743
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.06	)	$	(0.38	)	$	(0.64	)	$	(1.22	)	$	(0.10	)	$	(0.31	)	$	(0.34	)	$	(0.61	)

Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows:

In December 2018, the Company initiated a corporate restructuring to align with a strategic decision to continue the development of its drug candidates using external resources rather than internal resources. The restructuring will allow the Company to reduce costs while continuing to conduct clinical trials, to support existing partnerships that are advancing development of additional assets, and to pursue new licensing and partnership opportunities. This restructuring included a significant reduction in its workforce. The Company completed these restructuring activities in the second quarter of 2019.

During the six months ended June 30, 2019, the Company made cash payments of $0.3 million related to these severance benefits and recognized an immaterial amount of expense related to this plan. As of June 30, 2019, the remaining severance accrual was a de minimis amount.

The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.

The fair value of the Company’s Loan Agreement is considered to approximate its carrying value because it bears interest at a variable interest rate.

The Company measures the value of its investment in Reneo at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the three and ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, there were no observable price changes in identical or similar investments, nor were there any indications of impairment. As such, the value of the Company’s investment in Reneo was not remeasured.

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of ~~September~~June 30, ~~2018~~2019 and December 31, ~~2017~~2018 (in thousands):

	Changes in Level 3 instruments for the nine months ended September 30,												Changes in Level 3 instruments for the six months ended June 30,
													Balance at January 1		Net Change in fair value included in earnings			Purchases / Issuance		Sales / Repurchases		Balance at June 30,
2019
Warrant liability, related party													$	2,436	$	(1,196	)	$	—	$	—	$	1,240
Total													$	2,436	$	(1,196	)	$	—	$	—	$	1,240
	Balance at January 1		Net Change in fair value included in earnings			Purchases / Issuance		Sales / Repurchases			Balance at September 30,
2018
Warrant liability, related party		492		(610	)		500		—			382	$	492	$	(291	)	$	—	$	—	$	201
Total	$	492	$	(610	)	$	500	$	—		$	382	$	492	$	(291	)	$	—	$	—	$	201

2017
Warrant liability	$	167	$	—		$	—	$	(167	)	$	—
Total	$	167	$	—		$	—	$	(167	)	$	—

During the three and ~~nine~~six months ended ~~September~~June 30, 2019 and 2018, the Company recognized ~~a gain of $0.3 million and $0.6 million, respectively,~~gains related to the change in fair value of the Letter Agreement ~~Warrants. This gain was~~Warrants of $0.3 million for each of the three-month periods and gains of $1.2 million and $0.3 million, respectively, for the six-month periods. These gains were recognized as a component of other

income – related party in the Condensed Consolidated Statements of Operations. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of ~~September~~June 30, ~~2018~~2019 were:

Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.

On ~~October 26, 2018, we entered into amendments to the Letter Agreement Warrants with MacAndrews, which removed certain anti-dilution provisions of the Letter Agreement Warrants.~~

~~On November 6, 2018,~~July 9, 2019, the Company caused MacAndrews to purchase an additional ~~1,879,699~~1,212,121 shares of its Class A Common Stock under the terms of the ~~letter agreement entered into on July 30, 2018~~March 2019 Letter Agreement for ~~$2.5~~$2.0 million in cash.

As used in this Quarterly Report on Form 10-Q, the “Company”, the “Registrant”, “we” or “us” refer to vTv Therapeutics Inc. and “vTv LLC” refers to vTv Therapeutics LLC. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes that appear elsewhere in this report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, assumptions and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under “Part II, Other Information—Item 1A, Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

We are a clinical-stage biopharmaceutical company engaged in the ~~discovery and~~ development of orally administered small molecule drug candidates to fill significant unmet medical needs. ~~To date, we~~We have ~~primarily focused our efforts on advancing~~a pipeline of clinical drug candidates, led by our programs for the treatment of ~~mild~~ Alzheimer’s disease (“AD”) and diabetes.

~~As discussed further in “Our Alzheimer’s Program – Azeliragon – Phase 3 STEADFAST Study” below, both Parts A and B of our Phase 3 STEADFAST Study of the investigational medication~~ ~~azeliragon~~ (“TTP488”) in people with mild Alzheimer’s disease (the “STEADFAST Study”) failed to meet either of the co-primary efficacy endpoints. We are currently evaluating future development pathways for ~~TTP488~~ ~~based on the data received from the STEADFAST Study and feedback received from the Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”).~~

~~In addition to the~~ ~~azeliragon~~ ~~program, vTv is developing two compounds~~Our drug candidate for the treatment of ~~diabetes.~~AD, ~~TTP399~~ azeliragon (TTP488), is an orally administered, ~~liver-selective glucokinase activator~~small molecule antagonist targeting the receptor for advanced glycation endproducts (“~~GKA”~~RAGE”),. We began screening patients in June 2019 for ~~which we have completed our~~a Phase ~~2b clinical~~2 trial to evaluate azeliragon as a potential treatment of mild-AD in patients with type 2 ~~diabetes (the “AGATA Study”) and~~diabetes. We are ~~conducting an adaptive Phase 1b/2 clinical trial in~~currently investigating TTP399 as a treatment for type 1 diabetes ~~(the “SimpliciT-1 Study”~~in a Phase 2 study in partnership with JDRF International (“JDRF”). In addition, we are furthering the development of TTP273is, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (“GLP-1r”), ~~for which we have completed a Phase 2 clinical trial in~~our peroxisome proliferation activated receptor delta (“PPAR-δ”) agonist, and phosphodiesterase type ~~2 diabetes (the “LOGRA Study”~~4 (“PDE4”)~~, and that is currently being developed by Huadong under the Huadong License Agreement.~~

~~vTv also has two~~ programs in various stages of preclinical and clinical development for the treatment of inflammatory disorders that have been out-licensed, either in whole or in part, and one program for which we are seeking a partner to further develop.

~~We are currently exploring further development options for~~ ~~azeliragon~~ ~~and our other programs whether conducted internally, upon the receipt of additional funding, or~~ through partnerships with ~~other life sciences entities~~pharmaceutical partners via licensing arrangements. Finally, we continue to ~~either finance or perform the required development activities.~~advance our NRF2 pathway program via research agreements with academic and industry collaborators.

The following table summarizes our current drug candidates and their respective stages of development:

Sequential Phase 2 and Phase 3 ~~STEADFAST Study~~Studies in Mild-AD patients with Type 2 Diabetes

~~We initiated the STEADFAST Study~~In June 2019, we began screening patients for a clinical trial to evaluate azeliragon as a potential treatment of mild-AD in ~~April 2015 pursuant to a Special Protocol Assessment (“SPA”)~~patients with ~~the FDA. The study was~~type 2 diabetes that consists of sequential phase 2 and phase 3 studies operationally conducted ~~in the United States and certain English-speaking foreign countries~~ under a single clinical trial protocol ~~and was~~(the “488-305 Study”). The Phase 2 study is designed to enroll ~~800 mild AD~~approximately 100 patients ~~in total, divided equally across two independent 400-patient sub-studies, in which each subject received either a 5 mg/day dose~~to evaluate the impact of ~~azeliragon~~ ~~or placebo, randomized on a one-to-one basis, added to the standard~~six months of ~~care. In April 2018, we announced that the results from Part A did not meet either co-primary efficacy endpoint. Patients taking~~treatment with azeliragon ~~compared with placebo did not improve in~~on cognitive ~~or functional outcomes~~performance as measured by the change from baseline in the Alzheimer’s Disease Assessment ~~Scale-cognitive subscale~~Scale – Cognitive Subscale (“~~ADAS-cog”) and the Clinical Dementia Rating Scale Sum of Boxes (“CDR-sb”~~ADAS-COG₁₄”). ~~Following the April 2018 announcement of Part A topline results, we discontinued clinical trials involving~~ ~~azeliragon, including Part B of the STEADFAST study and open label extension.~~

~~At the time of the closure of Part B, a substantial number of participants completed 12 months of treatment under the study protocol. Based on the subpopulation data analyses from Part A and the prior~~ ~~azeliragon~~ trials, we prepared and submitted a revised Statistical Analysis Plan (“SAP”) to the FDA for Part B that pre-specified a target population for the primary study analysis at 12 months. In June 2018, we announced that the results from Part B did not meet either co-primary efficacy endpoint.

Relying upon the program’s Fast Track Designation status and study results to date, we have pursued discussions with the FDA and EMA to propose a pathway for further clinical development in support of regulatory approval of ~~azeliragon. On July 31, 2018, we submitted a full briefing book to the FDA in support of our request for a Type C meeting seeking development guidance for~~ ~~azeliragon. On September 17, 2018, we received a written response from the FDA to our Type C Meeting Request. In the response, the FDA advised that the efficacy of~~ ~~azeliragon~~ should be demonstrated in at least two adequate and well-controlled trials, unless under the exceptional circumstances in which a single trial might suffice as set forth in the FDA’s guidance document entitled “Providing Clinical Effectiveness for Human Drug and Biological Products”. We met with the Scientific Advice Working Party (“SAWP”) of the EMA on October 30, 2018, to discuss future development requirements in support of approval of ~~azeliragon~~ ~~in the European Union.~~ We expect to ~~receive formal guidance~~report top-line results from the ~~SAWP during~~Phase 2 study by the end of the fourth quarter of ~~2018.~~ 2020. The Phase 3 study is designed to enroll approximately 200 patients to evaluate the efficacy of 18 months of treatment with azeliragon on cognition and function. The design of the Phase 3 study may be adapted based on the results of the Phase 2 study.

In June 2019, we announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing TTP399 in adult patients with type 1 diabetes (“T1D”).

In this double-blind, placebo-controlled 12-week trial, the baseline mean HbA1c for the groups treated with TTP399 and placebo was 7.3% and 7.4%, respectively. Patients treated with TTP399 (n=8) showed a statistically significant mean reduction in HbA1c of 0.6% at 12 weeks, while the group treated with placebo (n=11) showed a mean increase in HbA1c of 0.1%, resulting in a mean HbA1c reduction of 0.7% in the TTP399 group relative to the placebo group (p=0.03). At the same time, trends toward decreased insulin usage were observed in the group treated with TTP399.

Patients in this study received insulin adjustments to optimize glucose levels. As a result, the primary analysis included a responder analysis in which a ‘treatment responder’ was defined as a patient who had a decrease in HbA1c at Week 12, no abnormal lactate or ketones detected in blood or urine during the study, and no increased time in Level 2 hypoglycemia (blood glucose <54 mg/dl). Of all study patients, there was a greater proportion of responders in the group treated with TTP399 (75%) than in the placebo group (9%) (p=0.006). Consistent with the treatment responder results, abnormal ketones were observed in plasma or urine in 63% of patients on placebo vs. 13% of patients treated with TTP399.

TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class. The study had no serious adverse event reported. The study also had no report of diabetic ketoacidosis or severe hypoglycemia.

We have begun enrollment in Part 2 of the Phase 2 Simplici-T1 trial and expect to report topline results from this portion of the study in the first quarter of 2020.

vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member

interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results under the VIE accounting model in its consolidated financial statements.

To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from up-front proceeds and research fees under collaboration and license agreements.

In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.

Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories and clinical research organizations (“CRO(s)”) in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits and related overhead expenses for personnel in research and development ~~functions and depreciation of leasehold improvements, laboratory equipment and computers.~~functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.

From our inception, including our predecessor companies, through ~~September~~June 30, ~~2018,~~2019, we have incurred approximately ~~$562.1~~$572.0 million in research and development expenses.

Our research and development expenses by project for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018 were as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017		2019		2018		2019		2018
Direct research and development expense:
Azeliragon	$	720	$	6,163	$	12,996	$	20,948	$	2,454	$	5,717	$	3,157	$	12,275
TTP399		66		60		587		199		530		306		1,130		521
TTP273		24		42		58		323
Other projects		85		290		427		942		143		251		334		375
Indirect research and development expense		1,803		2,434		6,167		7,160		1,101		2,320		2,429		4,366
Total research and development expense	$	2,698	$	8,989	$	20,235	$	29,572	$	4,228	$	8,594	$	7,050	$	17,537

We expect ~~to continue to incur~~our research and development expenses to increase as we ~~wind down~~continue screening and enrollment of the ~~STEADFAST~~Phase 2 portion of the 488-305 Study ~~and its open-label extension and~~ as ~~we further advance~~well as the ~~development~~continuing enrollment of ~~our diabetes drug candidates,~~patients in Part 2 of the Simplici-T1 study, subject to the availability of additional funding. ~~However, due to the termination of the STEADFAST Study and its open-label extension, we expect our overall research and development expense to decrease substantially.~~ To the extent we initiate further development of azeliragon or our other programs, our expenses, cash needs and operating losses may further increase.

The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:

the potential benefits of our candidates over other therapies;

•

~~the potential benefits of our candidates over other therapies;~~

our ability to market, commercialize and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;

future clinical trial results;

our ability to enroll patients in our clinical trials;

the timing and receipt of regulatory approvals, if any; and

the filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights, and the expense of doing so.

A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and related costs for employees in executive, finance, corporate development, human resources and administrative support functions. Other significant general and administrative expenses

include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs and information systems.

Interest Expense

Interest expense primarily consists of cash and non-cash interest expense related to our Loan Agreement. Cash interest on the Loan Agreement is recognized at a floating interest rate equal to 10.5% plus the amount by which the one-month London Interbank Offer Rate (“LIBOR”) exceeds 0.5%. Non-cash interest expense represents the amortization of the costs incurred in connection with the Loan Agreement, the allocated fair value of the warrants to purchase shares of our Class A Common Stock issued in connection with the Loan Agreement (the “Warrants”) and the accretion of the final interest payments (which will be paid in cash upon loan maturity), all of which are recognized in our Condensed Consolidated Statement of Operations using the effective interest method.

Results of Operations

Comparison of the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018

The following table sets forth certain information concerning our results of operations for the periods shown:

(dollars in thousands)	Three Months Ended September 30,									Three Months Ended June 30,
Statement of operations data:	2018			2017			Change			2019			2018			Change
Revenue	$	3,375		$	15		$	3,360		$	1,828		$	2,473		$	(645	)
Operating expenses:
Research and development		2,698			8,989			(6,291	)		4,228			8,594			(4,366	)
General and administrative		2,158			2,567			(409	)		2,392			2,737			(345	)
Total operating expenses		4,856			11,556			(6,700	)		6,620			11,331			(4,711	)
Operating loss		(1,481	)		(11,541	)		10,060			(4,792	)		(8,858	)		4,066
Interest income		13			35			(22	)		16			16			—
Interest expense		(822	)		(849	)		27			(514	)		(870	)		356
Other income, net		329			—			329			276			316			(40	)
Loss before income taxes		(1,961	)		(12,355	)		10,394			(5,014	)		(9,396	)		4,382
Income tax provision		—			—			—			100			200			(100	)
Net loss before noncontrolling interest		(1,961	)		(12,355	)		10,394			(5,114	)		(9,596	)		4,482
Less: net loss attributable to noncontrolling interest		(1,165	)		(8,705	)		7,540			(2,232	)		(6,524	)		4,292
Net loss attributable to vTv Therapeutics Inc.	$	(796	)	$	(3,650	)	$	2,854		$	(2,882	)	$	(3,072	)	$	190

Revenue was ~~$3.4~~$1.8 million for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~was insignificant~~$2.5 million for the three months ended ~~September~~June 30, ~~2017.~~2018. The reduction in revenue ~~earned during~~for the three months ended ~~September~~June 30, ~~2018~~2019 relates primarily to the completion of revenue recognized for the license performance obligation under our license agreement with Hangzhou Zhongmei Huadong ~~Reneo and~~Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”) in 2018. This decrease was offset by the recognition of $1.0 million of revenue under our license agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Newsoara License ~~Agreements.~~Agreement”), which is related to the adjustment in the transaction price due to the satisfaction of a contingent development milestone. We generally recognize the portion of the consideration ~~received~~ allocated to the license performance obligation for each of these agreements over the requisite knowledge transfer or research service periods in accordance with the applicable accounting guidance. ~~The portion~~However, the transaction price may change, causing the recognition of additional revenue ~~allocated to the other~~for these performance obligations, ~~under~~based upon the inclusion of additional variable consideration when it becomes probable that a development or sales milestone included in our license agreements will be ~~recognized as performance occurs.~~met.

Research and development expenses were ~~$2.7~~$4.2 million and ~~$9.0~~$8.6 million for the three months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively. The decrease in research and development expenses during the period of ~~$6.3~~$4.4 million, or ~~70.0%~~50.8%, was primarily due to a decrease in clinical trial costs of ~~$5.4~~$3.3 million for azeliragon which was mainly driven by ~~a decrease of $4.6 million related to~~ the termination of our STEADFAST and open-label extension (“OLE”) studies in early April 2018. ~~In addition,~~This decrease was offset, in part, by an increase in spending for the 488-305 Study. Additionally, we ~~incurred significantly lower~~saw a reduction in personnel costs ~~for compound manufacturing and other adjunct studies for~~ ~~TTP488~~ of approximately $1.0 million driven primarily by the corporate restructuring announced in ~~the three months ended September 30, 2018 compared to the three months ended September 30, 2017 due to their completion in early~~December 2018.

General and administrative expenses were ~~$2.2~~relatively consistent between periods at $2.4 million and ~~$2.6~~$2.7 million for the three months ended ~~September~~June 30, 2019 and 2018, ~~and 2017,~~ respectively. The decrease in general and administrative expenses during the period of $0.4 million, or 15.9%, was attributable to decreases in the amount of incentive compensation expected to be paid to our employees and decreases in share-based compensation expense recognized in the 2018 period.

Interest expense was ~~$0.8~~$0.5 million and $0.9 million for ~~each of~~ the three months ended ~~September~~June 30, 2019 and 2018, ~~and 2017.~~respectively. The decrease in interest expense was driven by principal payments made in accordance with the terms of our Loan Agreement. Interest expense relates to the cash and non-cash interest for our Loan Agreement which bears interest at 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%.

Comparison of the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018

The following table sets forth certain information concerning our results of operations for the periods shown:

(dollars in thousands)	Nine Months Ended September 30,									Six Months Ended June 30,
Statement of operations data:	2018			2017			Change			2019			2018			Change
Revenue	$	7,912		$	58		$	7,854		$	2,749		$	4,537		$	(1,788	)
Operating expenses:
Research and development		20,235			29,572			(9,337	)		7,050			17,537			(10,487	)
General and administrative		7,150			8,396			(1,246	)		4,778			4,992			(214	)
Total operating expenses		27,385			37,968			(10,583	)		11,828			22,529			(10,701	)
Operating loss		(19,473	)		(37,910	)		18,437			(9,079	)		(17,992	)		8,913
Interest income		47			95			(48	)		26			34			(8	)
Interest expense		(2,547	)		(2,240	)		(307	)		(1,140	)		(1,725	)		585
Other income, net		656			—			656			1,197			327			870
Loss before income taxes		(21,317	)		(40,055	)		18,738			(8,996	)		(19,356	)		10,360
Income tax provision		200			—			200			100			200			(100	)
Net loss before noncontrolling interest		(21,517	)		(40,055	)		18,538			(9,096	)		(19,556	)		10,460
Less: net loss attributable to noncontrolling interest		(14,697	)		(28,222	)		13,525			(4,059	)		(13,532	)		9,473
Net loss attributable to vTv Therapeutics Inc.	$	(6,820	)	$	(11,833	)	$	5,013		$	(5,037	)	$	(6,024	)	$	987

Revenue was ~~$7.9~~$2.7 million for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~was insignificant~~$4.5 million for the ~~nine~~six months ended ~~September~~June 30, ~~2017.~~2018. The reduction in revenue ~~earned during~~for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 relates primarily to the completion of revenue recognized for the license performance obligation under the Huadong ~~Reneo and~~License Agreement in 2018. This decrease was offset by the recognition of $1.0 million of revenue under the Newsoara License ~~Agreements.~~Agreement related to the adjustment in the transaction price due to the satisfaction of a contingent development milestone. We generally recognize the portion of the consideration ~~received~~ allocated to the license performance obligation for each of these agreements over the requisite knowledge transfer or research service periods in accordance with the

applicable accounting guidance. ~~The portion~~However, the transaction price may change, causing the recognition of additional revenue ~~allocated to the other~~for these performance obligations, ~~under~~based upon the inclusion of additional variable consideration when it becomes probable that a development or sales milestone included in our license agreements will be ~~recognized as performance occurs.~~met.

Research and development expenses were ~~$20.2~~$7.1 million and ~~$29.6~~$17.5 million for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, respectively. The decrease in research and development expenses during the period of ~~$9.3~~$10.5 million, or ~~31.6%~~59.8%, was primarily due ~~to:~~

General and administrative expenses were ~~$7.2~~relatively consistent between periods at $4.8 million and ~~$8.4~~$5.0 million for the ~~nine~~six months ended ~~September~~June 30, 2019 and 2018, ~~and 2017,~~ respectively. The decrease in general and administrative expenses during the period of $1.2 million, or 14.8%, was primarily attributable to decreases in the amount of incentive compensation expected to be paid to our employees and decreases in professional fees incurred in the 2018 period.

Interest expense was ~~$2.5~~$1.1 million and ~~$2.2~~$1.7 million for the ~~nine~~six months ended ~~September~~June 30, 2019 and 2018, ~~and 2017,~~ respectively. The decrease in interest expense was driven by principal payments made in accordance with the terms of our Loan Agreement. Interest expense relates to the cash and non-cash interest for our Loan Agreement which bears interest at 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%~~. The increase in interest expense relates to the increased principal balance outstanding during the 2018 period as the second tranche of the Loan Agreement was funded in March 2017~~.

As of ~~September~~June 30, ~~2018,~~2019, we have an accumulated deficit of ~~$189.0~~$217.6 million as well as a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of ~~September~~June 30, ~~2018,~~2019, our liquidity sources included cash and cash equivalents of ~~$3.8~~$1.5 million, ~~and~~ the ~~$5.0~~$7.0 million of remaining funds available under the letter agreements entered into with MacAndrews and Forbes Group LLC (“MacAndrews”) (the “Letter Agreements”). and amounts due under our license agreements with Newsoara and JDRF International, net of applicable taxes. Based on our current operating plan, we believe that our current cash and cash equivalents and remaining funds available under the Letter Agreements will allow us to meet our liquidity requirements into ~~December 2018.~~the third quarter of fiscal 2019. These factors raise substantial doubt regarding our ability to continue as a going concern. ~~In addition~~

We began screening patients for the 488-305 Study in June 2019 and are continuing to available cash and cash equivalents and available funds discussed above, we are seeking possible partnering opportunities for our GKA, GLP-1r and other drug candidates which we believe may provide additional cash for use in our operations and the continuationconduct Part 2 of the Phase 2 clinical trial of TTP399 in patients with type 1 diabetes. In order to complete these trials ~~for our drug candidates.~~and continue the Company’s operations, we will require additional financing. We are ~~also pursuing other sources of additional~~evaluating several financing strategies to provide ~~flexibility to~~continued funding which may include additional direct equity investments or future public offerings of our ~~operating plan.~~common stock. The timing and availability of such ~~additional~~ financing is not yet ~~known and the failure of the STEADFAST Study to meet either of its clinical endpoints may make it more difficult for us to obtain such financing.~~ known.

~~The Company has~~We have entered into the Letter Agreements with MacAndrews. Under the terms of ~~these letter agreements,~~ the ~~Company has~~Letter Agreements, we have the right to sell to MacAndrews shares of ~~its~~ Class A Common Stock at a specified price per share, and MacAndrews has the right (exercisable up to three times) to require ~~the Company~~us to sell to it shares of Class A Common Stock at the same price. ~~An aggregate of~~ ~~$10.0 million worth of Class A Common Stock may be sold under each of the Letter Agreements (whether at the Company’s or MacAndrews’ option).~~ In addition, in connection with the entrance into certain of these Letter Agreements, ~~the Company~~we also

issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of ~~the Company’s~~our Class A Common Stock. ~~On October 26, 2018, we entered into amendments to the Letter Agreement Warrants with MacAndrews, which removed certain anti-dilution provisions of the Letter Agreement Warrants.~~

~~The critical~~Certain terms of these Letter Agreements are set forth in the table below:

	December 5, 2017 Letter Agreement		July 30, 2018 Letter Agreement		December 11, 2018 Letter Agreement		March 18, 2019 Letter Agreement
Aggregate dollar value to be sold under agreement	$10.0 million		$10.0 million		$10.0 million		$9.0 million
Specified purchase price per share	$	4.38	$	1.33	$	1.84	$	1.65
Expiration date of letter agreement	December 5, 2018		July 30, 2019		December 11, 2019		March 18, 2020
Shares available to be issued under related warrants		198,267		518,654		340,534		—
Exercise price of related warrants	$	5.04	$	1.53	$	2.12	$	—
Expiration date of related warrants	December 5, 2024		July 30, 2025		December 11, 2025
Total shares issued as of June 30, 2019		2,283,105		7,518,797		5,434,783		1,212,121
Remaining shares to be issued as of June 30, 2019		—		—		—		4,242,425

In October 2016, we and vTv LLC entered into the Loan Agreement, under which we have borrowed $20.0 million. Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%.

We borrowed the first tranche of $12.5 million upon the close of the Loan Agreement in October 2016. The first tranche required only monthly interest payments until May 1, 2018, followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on May 1, 2020. In addition, a final payment for the first tranche loan equal to $0.8 million will be due on May 1, 2020, or such earlier date specified in the Loan Agreement. We borrowed the second tranche of $7.5 million in March 2017. The second tranche requires only monthly interest payments until October 1, 2018, followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on October 1, 2020. In addition, a final payment for the second tranche loan equal to $0.5 million will be due on October 1, 2020, or such earlier date specified in the Loan Agreement. The availability of the third tranche of $5.0 million expired unused on June 30, 2017.

If we repay all or a portion of the loan prior to the applicable maturity date, we will pay the Lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance equal to 4.0% during the first 18 months following the funding of the second tranche and 2.0% thereafter.

In connection with the Loan Agreement, we have issued to the Lenders warrants to purchase shares of our Class A Common Stock (the “Warrants”). On October 28, 2016, we issued Warrants to purchase 152,580 shares of our Class A Common Stock at a per share exercise price of $6.39 per share, which aggregate exercise price represents 6.0% of the principal amount borrowed under the first tranche of the Loan Agreement and 3.0% of the amount available under the second tranche of the Loan Agreement. On March 24, 2017, in connection with the funding of the second tranche, we issued Warrants to purchase 38,006 shares of our Class A Common Stock at a per share exercise price of $5.92 per share, which aggregate exercise price represents 3.0% of the principal amount of the second tranche. In each instance, the Warrants have an exercise price equal to the lower of (a) the volume weighted average price per share of our Class A Common Stock, as reported on the principal stock exchange on which our Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of our Class A Common Stock on the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.

The Loan Agreement includes customary affirmative and restrictive covenants, including, but not limited to, restrictions on the payment of dividends or other equity distributions and the incurrence of debt or liens upon the assets of the Company or its subsidiaries. The Loan Agreement does not contain any financial maintenance covenants other than a requirement to maintain a minimum cash balance of not less than $2.5 million in a deposit account pledged to secure the Loan Agreement and subject to an account control agreement. The ~~minimum cash balance covenant was included as part of an amendment to the Loan Agreement in connection with our entry into the Huadong License Agreement in December 2017. The~~ Loan Agreement includes customary events of default, including payment defaults, covenant defaults, and material adverse change default. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5.0% will be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. ~~As a result of the termination of the STEADFAST Study, we~~We have granted the Lenders a first priority security interest in all of our intellectual property, subject to certain limited exceptions.

For the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, our net cash used in operating activities decreased ~~$17.2~~$3.8 million from the ~~nine~~six months ended ~~September~~June 30, ~~2017. The decreased use of cash~~2018. This decrease was driven ~~primarily~~ by ~~lower expenses incurred~~the reduction in the ~~nine~~net loss for the six months ended ~~September~~June 30, 2019 which was primarily driven by the cessation of the STEADFAST and related OLE studies in April 2018. This reduction in net loss was offset by the receipt of approximately $7.8 million in receivables related to an upfront payment for our Huadong License Agreement during the six months ended June 30, 2018.

For the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017,~~2018, net cash ~~used in~~provided by investing activities was insignificant.

For the ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, net cash provided by financing activities ~~was impacted~~increased by $6.8 million from the ~~receipt~~six months ended June 30, 2018, driven by increases in funding received from sales of ~~$15.0 million for the issuance of shares of our~~ Class A Common Stock ~~under~~pursuant to the Letter ~~Agreements.~~Agreements and through a registered direct offering in 2019. Such ~~receipts~~increases in funding were offset by ~~$2.7 million~~higher uses of cash to repay the principal ~~payments required by~~portion of our ~~Loan Agreement. For~~outstanding notes payable in 2019 pursuant to the ~~nine months ended September 30, 2017, net cash provided by financing activities was $7.5 million, as we borrowed~~payment terms of the ~~second tranche under our~~ Loan Agreement.

To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. We anticipate that we will need substantial additional funding in connection with our continuing operations.

Based on our current operating plan, we believe that our current cash and cash equivalents, ~~and~~ remaining funds available under the Letter Agreements and amounts expected to be collected under our collaboration agreements will allow us to meet our liquidity requirements into ~~December 2018.~~the third quarter of 2019. We began screening patients for the 488-305 Study in June 2019 and are continuing to conduct Part 2 of the Phase 2 clinical trial of TTP399 in patients with type 1 diabetes. In ~~addition~~order to ~~the available cash~~complete these trials and cash equivalents and other sources of liquidity, we are seeking possible additional partnering opportunities for our GKA, GLP-1r and other drug candidates which we believe may provide additional cash for use incontinue our operations, ~~and the continuation of the clinical trials for our drug candidates.~~we will require additional financing. We ~~may also pursue other sources of~~are evaluating several financing strategies to provide ~~flexibility to~~continued funding, which may include additional direct equity investments or future public offerings of our ~~operating plan.~~common stock. The timing and availability of such financing is not yet ~~known and the failure of the STEADFAST Study to meet either of its co-primary endpoints may make it more difficult for us to obtain such financing.~~ known.

We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates.

Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. We do not currently have any committed external source of funds other than those available through the March 2019 Letter ~~Agreements.~~Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate our research and development programs or commercialization efforts, which could adversely affect our business prospects.

As of September 30, 2018, there were no material changes to our total contractual cash obligations, as set forth in the contractual obligations and commitments disclosure included in Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2017.

We enter into contracts in the normal course of business with CROs for clinical trials and clinical supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes, which generally provide for termination or cancellation within 30 days of notice.

We have entered into the Letter Agreements with MacAndrews and Forbes Group LLC which, as of ~~September~~June 30, ~~2018,~~2019, provide us the right to sell to MacAndrews an additional ~~3,759,399~~ 4,242,425 shares of our Class A Common Stock at a price ~~equal to $1.33~~of $1.65 per share. Further, MacAndrews has the right (exercisable up to three times) to require us to sell to it an equal number of shares of Class A Common Stock at the same price. As of ~~September~~June 30, ~~2018~~2019, we had received funding of ~~$15.0~~$32.0 million under the Letter Agreements and, in exchange, had issued a total of ~~6,042,503~~16,448,806 shares of our Class A Common Stock.

For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, ~~2017.~~2018. Significant changes made to our critical accounting policies and estimates in ~~2018~~2019 with respect to our adoption of Accounting Standards Codification Topic ~~606 “Revenue From Contracts with Customers”~~842 “Leases” are discussed within Note 2 of the Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q.

This quarterly report includes certain forward-looking statements within the meaning of the federal securities laws regarding, among other things, our management’s intentions, plans, beliefs, expectations or predictions of future events, which are considered

forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based upon assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you read this quarterly report, you should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions, including those described under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this Quarterly Report on Form 10-Q. Although we believe that these forward-looking statements are based upon reasonable assumptions, you should be aware that many factors, including those described under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K and under Item 1A of Part II of this

Quarterly Report on Form 10-Q, could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements.

Our forward-looking statements made herein are made only as of the date of this quarterly report. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this quarterly report.

See discussion of recent accounting pronouncements in Note 2, “Summary of Significant Accounting Policies”, to the Condensed Consolidated Financial Statements in this Form 10-Q.

Our Loan Agreement bears interest at a floating rate equal to 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%. A one percent increase in the variable rate of interest on the Loan Agreement would increase interest expense by approximately ~~$0.2~~$0.1 million annually based on the amounts currently outstanding. We do not currently hedge our interest rate exposure.

Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality. The securities in our investment portfolio are not leveraged and are, due to their short-term nature, subject to minimal interest rate risk. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the value of our investment portfolio.

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of ~~September~~June 30, ~~2018.~~2019. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of ~~September~~June 30, ~~2018,~~2019, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized and

reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures

may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.

There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on the SEC’s website http://www.sec.gov.

In addition to the ~~risk factors listed below and~~ other information in this report, investors should carefully consider the risk factors set forth under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December 31, ~~2017.~~2018.

~~We may not be able to continue the development of, obtain regulatory approval for, or successfully commercialize azeliragon.~~

~~We have expended considerable resources and efforts on the development of~~ ~~azeliragon. In April 2018, we announced that results from Part A of our Phase 3 STEADFAST Study of the investigational medication~~ ~~azeliragon~~ (TTP488) in people with mild Alzheimer’s disease (the “STEADFAST Study”) did not meet either co-primary efficacy endpoint as required by the Special Protocol Agreement (“SPA”) with the FDA. Following the April 2018 announcement, we discontinued clinical trials involving ~~azeliragon, including Part B and open label extension.~~

~~At the time of the closure of Part B, a substantial number of participants completed 12 months of treatment under the study protocol. Based on the subpopulation data analyses from Part A and the prior~~ ~~azeliragon~~ trials, we prepared and submitted a revised Statistical Analysis Plan (“SAP”) to the Food and Drug Administration (“FDA”) for Part B that pre-specified a target population for the primary study analysis at 12 months. In June 2018, we announced that the results from Part B did not meet either co-primary efficacy endpoint.

Relying upon the program’s Fast Track Designation status and study results to date, we have pursued discussions with the FDA and European Medicines Agency (“EMA”) to propose a pathway for further clinical development in support of regulatory approval of ~~azeliragon. On July 31, 2018, we submitted a full briefing book to the FDA in support of our request for a Type C meeting seeking development guidance for~~ ~~azeliragon. On September 17, 2018, we received a written response from the FDA to our Type C Meeting Request. In the response, the FDA advised that the efficacy of~~ ~~azeliragon~~ should be demonstrated in at least two adequate and well-controlled trials, unless under the exceptional circumstances in which a single trial might suffice as set forth in the FDA’s guidance document entitled “Providing Clinical Effectiveness for Human Drug and Biological Products”.

~~The failure of Parts A and B of the STEADFAST Study to meet their co-primary endpoints is expected to delay the potential commercialization of~~ ~~azeliragon~~ and may make such commercialization more difficult or impossible. We will need to commence and complete additional clinical trials that satisfy the specified primary endpoint criteria, manage clinical and manufacturing activities, obtain necessary regulatory approvals from the FDA or other comparable regulatory authorities, and, if approved, successfully market and commercialize ~~azeliragon. If we continue with the development of~~ ~~azeliragon, there is no guarantee that we will be able to successfully complete these steps, and if we do not continue with the development of~~ ~~azeliragon~~, then we may not be able to continue our business in its current form and will be required to pursue alternative business strategies. As an organization, we have never completed a successful Phase 3 clinical trial or submitted a New Drug Application before, and we may be unsuccessful in doing so for ~~azeliragon~~.

We require additional funding and there is a substantial doubt about our ability to continue as a going concern; if we fail to raise additional funding we will cease operations and/or seek protection under applicable bankruptcy laws.

We require additional financing in order to continue to fund operations, and there is a substantial doubt about our ability to continue as a going concern. No assurance can be given that we will be successful in obtaining any such financing on acceptable terms, if at all, or if secured, that such financing will provide for funding or payments to us sufficient to continue to fund operations. After giving effect to our existing sources of liquidity, including the Letter Agreements, we believe we have cash sufficient to fund operations only into December 2018. In the absence of the receipt of additional financing prior to such time, we will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws.

Our recurring losses, accumulated deficit and our current levels of cash and cash equivalents raise substantial doubt about our ability to continue as a going concern as of the date of this report. If we are unable to continue as a going concern, we may have to liquidate our assets and it is likely that investors will lose all or a significant part of their investments. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all, and such additional funding may cause substantial dilution to our existing investors. Further, if adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs.

~~Our stock price may decline and we may not be able to maintain compliance with NASDAQ listing requirements~~

~~Our common stock is listed on The NASDAQ Capital Market, which imposes certain minimum continued listing requirements.~~ ~~If compliance with these requirements is not maintained, NASDAQ may make a determination to delist our common stock.~~

There were no sales of unregistered equity securities during the three months ended ~~September~~June 30, ~~2018~~2019 that have not previously been included in a Current Report on Form 8-K.

Our ability to pay dividends is restricted by our Loan Agreement. See “Management's Discussion and Analysis of Financial Condition and Results of Operations”.

On November 6, 2018, the Company caused MacAndrews to purchase an additional 1,879,699 shares of its Class A Common Stock under the terms of the letter agreement entered into on July 30, 2018 for $2.5 million in cash.None.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Delaware		47-3916571
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

4170 Mendenhall Oaks Pkwy High Point, NC		27265
(Address of principal executive offices)		(Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value $0.01 per share	VTVT	NASDAQ Capital Market

Class of Stock	Shares Outstanding as of ~~November 8, 2018~~July 31, 2019
Class A common stock, par value $0.01 per share		~~17,652,148~~31,038,903
Class B common stock, par value $0.01 per share		23,094,221

		PAGE NUMBER

PART I – FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2018~~2019 (Unaudited) and December 31, ~~2017~~2018	4

	Unaudited Condensed Consolidated Statements of Operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018	5

	Unaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the ~~nine~~three and six months ended ~~September~~June 30, 2019 and 2018	6

	Unaudited Condensed Consolidated Statements of Cash Flows for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 and ~~2017~~2018	78

	Notes to Unaudited Consolidated Financial Statements	89

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31

Item 4.	Controls and Procedures	31

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	32

Item 1A.	Risk Factors	32

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3332

Item 3.	Defaults Upon Senior Securities	3332

Item 4.	Mine Safety Disclosures	3332

Item 5.	Other Information	3432

Item 6.	Exhibits	3533

	Signatures	3634

	For the Nine Months Ended September 30,		For the Six Months Ended June 30,
	2018	2017	2019	2018
Expected volatility	71.15% - 99.23%	76.88% - 85.93%	115.29% - 117.94%	71.15% - 99.23%
Expected life of option, in years	5.7 - 6.0	5.8 - 6.0	5.8 - 6.0	5.7 - 6.0
Risk-free interest rate	2.69% - 2.84%	1.87% - 2.24%	1.88% - 2.64%	2.69% - 2.81%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

Emerging growth company	☒

	September 30, 2018		December 31, 2017		June 30, 2019		December 31, 2018
Cash and cash equivalents	$	3,766	$	11,758	$	1,462	$	1,683
Restricted cash and cash equivalents		—		162
Restricted cash and cash equivalents, long-term		2,500		2,500		2,500		2,500
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$	6,266	$	14,420	$	3,962	$	4,183

	Number of Shares			Weighted- Average Exercise Price		Number of Shares			Weighted- Average Exercise Price
Awards outstanding at December 31, 2017		1,960,732		$	8.50
Awards outstanding at December 31, 2018							1,767,503		$	8.57
Granted		102,750			3.25		995,500			2.26
Forfeited		(280,794	)		6.17		(186,292	)		5.99
Awards outstanding at September 30, 2018		1,782,688		$	8.57
Options exercisable at September 30, 2018		1,173,468		$	10.20
Awards outstanding at June 30, 2019							2,576,711		$	6.32
Options exercisable at June 30, 2019							1,338,567		$	9.45
Weighted average remaining contractual term	7.3 Years					6.8 Years
Options vested and expected to vest at September 30, 2018		1,742,506		$	8.64
Options vested and expected to vest at June 30, 2019							2,524,818		$	6.39
Weighted average remaining contractual term	7.7 Years					8.0 Years

	Number of Shares			Weighted- Average Grant Date Fair Value
Awards outstanding at December 31, 2017		35,000		$	5.81
Vested		(11,667	)		5.81
Awards outstanding at September 30, 2018		23,333		$	5.81
RSUs expected to vest at September 30, 2018		22,896		$	5.81

	September 30, 2018		September 30, 2017		June 30, 2019		June 30, 2018
Class B Common Stock ⁽¹⁾		23,094,221		23,119,246		23,094,221		23,094,221
Common stock options granted under the Plan		1,782,688		1,952,399		2,576,711		1,926,925
Restricted stock units		23,333		35,000		11,667		23,334
Common stock options granted under Letter Agreement		3,759,399		—
Common stock options granted under Letter Agreements						4,242,425		1,141,553
Common stock warrants		907,507		190,586		1,248,041		388,853
Total		29,567,148		25,297,231		31,173,065		26,574,886

Exhibit Number		Description

~~10.1~~		~~Letter Agreement, dated as of July 30, 2018, by and between MacAndrews & Forbes Group LLC and vTv Therapeutics Inc.~~

~~10.2~~		~~Form of Securities Purchase Agreement to Purchase Class A Common Stock, by and between MacAndrews & Forbes Group LLC and vTv Therapeutics Inc.~~

31.1		Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Document

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

		VTV THERAPEUTICS INC.
		(Registrant)

By:		/s/ Stephen L. Holcombe
		Stephen L. Holcombe
		President and Chief Executive Officer

By:		/s/ Rudy C. Howard
		Rudy C. Howard
		Chief Financial Officer